Mode
Text Size
Log in / Sign up
Phase 2 Completed N=308 Randomized Double-blind Prevention

Late Phase 2 Study of OPC-12759 Ophthalmic Suspension

Dry Eye Syndromes
Source: ClinicalTrials.gov NCT00475319 ↗
Enrolled (actual)
308
Serious AEs
0.3%
Results posted
Jun 2013
Primary outcomePrimary: Change in Fluorescein Corneal Staining (FCS) Score From Baseline to Last Observation Carried Forward (LOCF) — -3.5; -3.7; -1.8 FCS score — p=0.001

Summary

The purpose of this study is to evaluate the dose-response of OPC-12759 suspension in dry eye patients

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Fluorescein Corneal Staining (FCS) Score From Baseline to Last Observation Carried Forward (LOCF)
-3.5; -3.7; -1.8 0.001 sig
SECONDARY
Change in Lissamine Green Conjunctival Staining (LGCS) Score From Baseline to Last Observation Carried Forward (LOCF)
-4.0; -4.5; -1.9 0.001 sig

Eligibility Criteria

Inclusion Criteria

  • Outpatient
  • Subjective complaint of dry eye that has been present for minimum 20 months
  • Ocular discomfort severity is moderate to severe
  • Corneal - conjunctival damage is moderate to severe
  • Unanesthetized Schirmer's test score of 5mm/5minutes or less
  • Best corrected visual acuity of 0.2 or better in both eyes

Exclusion Criteria

  • Presence of anterior segment disease or disorder other than that associated with keratoconjunctivitis sicca
  • Ocular hypertension patient or glaucoma patient with ophthalmic solution
  • Anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study
  • Anticipated use of contact lens during the study
  • Patient with punctal plug
  • Any history of ocular surgery within 12 months
  • Female patients who are pregnant, possibly pregnant or breast feeding
  • Known hypersensitivity to any component of the study drug or procedural medications
  • Receipt of any investigational product within 4 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00475319). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search